The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges

被引：12
|
作者：
Yang, Pingping [1 ,2 ]
Huang, Tianlun [2 ]
Xu, Gaosi [2 ]
机构：
[1] Nanchang Univ, Med Ctr, Grad Sch, Nanchang, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 2, Dept Nephrol, 1 Minde Rd, Nanchang 330006, Peoples R China
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2016年 / 65卷 / 09期
基金：
中国国家自然科学基金;
关键词：
Finerenone; Mineralocorticoid receptor antagonists; Diabetic kidney disease; Endothelin; CHRONIC HEART-FAILURE; ANGIOTENSIN-ALDOSTERONE SYSTEM; CONVERTING ENZYME-INHIBITOR; INSULIN-RESISTANCE; BAY; 94-8862; EMERGING PARADIGM; VS; EPLERENONE; TASK-FORCE; BLOCKADE; NEPHROPATHY;
D O I：
10.1016/j.metabol.2016.06.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with diabetic kidney disease (DKD) who received angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may show high serum levels of aldosterone. Finerenone (BAY 94-8862), a novel non-steroidal mineralocorticoid receptor antagonist (MRA), which is more selective for the mineralocorticoid receptor (MR) than spironolactone and has greater affinity for the MR than eplerenone, can reduce the concentration of aldosterone. The interaction between aldosterone and endothelin, together with their regulation on inflammation, oxidative stress and fibrosis, indicates that finerenone combined with atrasentan may play synergetic roles in reversing the procession of DKD. The present review, for the first time, discussed the mechanisms of finerenone combination with ACEI, ARBs, statins, and the endothelin receptor antagonist atrasentan. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：1342 / 1349
页数：8
相关论文
共 50 条
  • [31] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Srikanth Palanisamy
    Mario Funes Hernandez
    Tara I. Chang
    Kenneth W. Mahaffey
    Cardiology and Therapy, 2022, 11 : 337 - 354
  • [32] Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM
    Long, Allissa
    Salvo, Marissa
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (09) : 1041 - 1048
  • [33] Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
    Gerisch, Michael
    Heinig, Roland
    Engelen, Anna
    Lang, Dieter
    Kolkhof, Peter
    Radtke, Martin
    Platzek, Johannes
    Lovis, Kai
    Rohde, Gabriele
    Schwarz, Thomas
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (11) : 1546 - 1555
  • [34] Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
    Kolkhof, Peter
    Delbeck, Martina
    Kretschmer, Axel
    Steinke, Wolfram
    Hartmann, Elke
    Baerfacker, Lars
    Eitner, Frank
    Albrecht-Kuepper, Barbara
    Schaefer, Stefan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (01) : 69 - 78
  • [35] Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease Role of Oxidative Stress
    Lattenist, Lionel
    Lechner, Sebastian M.
    Messaoudi, Smail
    Le Mercier, Alan
    El Moghrabi, Soumaya
    Prince, Sonia
    Bobadilla, Norma A.
    Kolkhof, Peter
    Jaisser, Frederic
    Barrera-Chimal, Jonatan
    HYPERTENSION, 2017, 69 (05) : 870 - +
  • [36] Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Alexandrou, Maria-Eleni
    Theodorakopoulou, Marieta P.
    Sarafidis, Pantelis A.
    KIDNEY AND DIALYSIS, 2022, 2 (02): : 163 - 182
  • [37] Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?
    Huang, Bi
    Mcdowell, Garry
    Rao, Anirudh
    Lip, Gregory Y. H.
    JOURNAL OF HYPERTENSION, 2024, 42 (03) : 396 - 398
  • [38] Finerenone (Kerendia) for Diabetic Kidney Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1668): : 15 - 16
  • [39] Effects of Non-Steroidal Mineralocorticoid Antagonist (Finerenone) in Western Diet-Induced Kidney Disease
    Myakala, Komuraiah
    Ribeiro, Patricia de Carvalho
    Wang, Xiaoxin
    Korolowicz, Kyle E.
    Rodriguez, Olga C.
    Albanese, Chris
    Levi, Moshe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 668 - 668
  • [40] FIDELIO STUDY: SIGNIFICANCE AND PLACE OF FINERENONE AS NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST IN THERAPY OF PATIENTS WITH CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES
    Shamkhalova, Minara S.
    Sukhareva, Olga Yu.
    Yevloyeva, Madina I.
    DIABETES MELLITUS, 2023, 26 (06): : 603 - 614
12345